The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Gene location of IDDM == Genome-wide linkage analysis could be used for identification in susceptibility genes of insulin-dependent (type I) diabetes mellitus (IDDM). This analysis verifies that eighteen different genome regions are predisposed to insulin-dependent (type I) diabetes mellitus(IDDM). There are 18 different symbols of genome region, which is labeled from IDDM1 to IDDM18. The MHC HLA gene (IDDM1) and the insulin gene INS (IDDM2) are the major genetic candidates in the development of insulin-dependent (type I) diabetes mellitus(IDDM), which are located on the chromosome 6p21.3 and chromosome 11p15 respectively. IDDM3, IDDM4, IDDM5 IDDM7 reside in chromosome 15q26, chromosome 11q13, chromosome 6q25 and 2q31 respectively.IDDM11 (insulin-dependent diabetes mellitus 11) is one of the susceptibility genes for IDDM which locates on chromosome 14q24.3-q31. This loci is identified by linkage to D14S67 marker via a sibling-pair linkage analysis Based on the previous study, the biological behavior of IDDM11is different to HLA region genes so that IDDM11 is less predisposing to HLA. Moreover, IDDM11 has more involvement on the families that are less predisposing to HLA, while IDDM11 has less involvement on the families that are more predisposing to HLA. The rest of susceptibility genes locus in insulin-dependent (type I) diabetes mellitus (IDDM)are shown in table 1. Table 1 The locus for susceptibility genes for IDDM.
Hong Kong is represented in the National People's Congress by 36 deputies chosen through an electoral college and 203 delegates in the National Committee of the Chinese People's Political Consultative Conference appointed by the central government.
Schabowski gave a confusing answer that asserted it was necessary because West Germany had exhausted its capacity to accept fleeing East Germans, then remembered the note he had been given and added that a new regulation had been drafted to allow permanent emigration at any border crossing. This caused a stir in the room; amid several questions at once, Schabowski expressed surprise that the reporters had not yet seen this regulation, and started reading from the note. After this, a reporter, either Ehrman or Bild-Zeitung reporter Peter Brinkmann, both of whom were sitting in the front row at the press conference, asked when the regulations would take effect. After a few seconds' hesitation, Schabowski replied, "As far as I know, it takes effect immediately, without delay" (German: Das tritt nach meiner Kenntnis ... ist das sofort ... unverzüglich). This was an apparent assumption based on the note's opening paragraph; as Beil attempted to interject that it was up to the Council of Ministers to decide when it took effect, Schabowski proceeded to read this clause, which stated it was in effect until a law on the matter was passed by the Volkskammer. Crucially, a journalist then asked if the regulation also applied to the crossings to West Berlin. Schabowski shrugged and read item 3 of the note, which confirmed that it did. After this exchange, Daniel Johnson of The Daily Telegraph asked what this law meant for the Berlin Wall. Schabowski sat frozen before giving a rambling statement about the Wall being tied to the larger disarmament question.
The Combine have inspired the creation of several items of merchandise for the Half-Life series. A plush toy was created by Valve, based on the synthetic tripod Hunters introduced in Episode Two. Sold and distributed via Valve's online store, the toy was released in February 2008. In addition, Valve has produced t-shirts depicting the Combine's idea of humanity's evolution, from ape to Combine Overwatch soldier mirroring The March of Progress, and a lithograph displaying twelve pieces of concept art for the Combine soldier. The Combine have received a positive reaction from critics. 1UP.com praised the "epic feel" built up by the Combine and their harsh rule of City 17 in Half-Life 2, stating that this created "a world governed by newspeak, decorated with urban decay, and lacking any hope". GameSpot echoed this praise, saying that the "vision of a dystopian police state is chillingly effective". PC Zone described the appearance of the Combine's soldiers as "Stormtrooper-like". While stating that overall the artificial intelligence for the game was "extremely competent", they expressed the opinion that Combine non-player characters "could have used better survival instincts", citing their reluctance to take cover and tendency to charge at the player and into a shotgun blast. GameSpot noted that their AI had been slightly improved in Episode One.
Sources: en.wikipedia.org
LiveNation (which already operates music venues at the site) will revamp the Budweiser Stage Amphitheatre into an indoor/outdoor facility with a capacity of up to 20,000 people in the summer and nearly 9,000 in winter. Austrian company Therme Group will develop the west island. A new large facility will cover most of the island. The facility will include indoor and outdoor pools, a spa, waterslides, restaurants, and a botanical garden. Outside of the facility, it will build a 12 acres (4.9 ha) public park and beach. The projected admission price for indoor activities is about $40 per person for full-day admittance. A third company proposed to build a zip-line and adventure park but pulled out of the project. The company and the government could not come to terms on the lease. Private sector investments are expected to be about $500 million. Public sector investment was not disclosed. A review process for environmental, heritage, and public consultation will likely extend into 2023. Construction is scheduled to begin in 2024, with a 2030 completion. In February 2022, Toronto city council voted to adopt a process to create an approvals process for the Province's plan for the redevelopment of Ontario Place. This process generally follows the city's traditional development approvals process, notwithstanding Ontario Place is predominately constructed on Provincially-owned land. Based on this timeline, a rezoning application is expected in late 2022 and a site plan approval process began in 2023. The Cinesphere was closed for renovations.
=== Complications === Pressure ulcers can trigger other ailments, cause considerable suffering, and can be expensive to treat. Some complications include autonomic dysreflexia, bladder distension, bone infection, pyarthrosis, sepsis, amyloidosis, anemia, urethral fistula, gangrene and very rarely malignant transformation (Marjolin's ulcer – secondary carcinomas in chronic wounds). Sores may recur if those with pressure ulcers do not follow recommended treatment or may instead develop seromas, hematomas, infections, or wound dehiscence. Paralyzed individuals are the most likely to have pressure sores recur. In some cases, complications from pressure sores can be life-threatening. The most common causes of fatality stem from kidney failure and amyloidosis. Pressure ulcers are also painful, with individuals of all ages and all stages of pressure ulcers reporting pain.
== Further reading == Jarvis, Lisa M.; Morrison, Jessica (2015-10-24). "What's nitro cold brew, and why is it so damn delicious?". Chemical & Engineering News. Calderone, Julia; Bartels, Meghan (2016-06-01). "Why Starbucks is pumping nitrogen into its coffee". Business Insider. The Best Coffee For Cold Brew
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.